Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dont know if it will help but BMT on reddit said he is down 117,000......misery loves company.
wise man, there is still a lot of value in this stock once all the dust settles from this disappointment.
Hotel Delta.....Im going to hold as I need .20 to break even, down 51,000 right now.
Rubberneck2 I feel your pain, this is money that I had no business throwing away especially on a penny stock. I never learn my lesson but now that I am such deep shit with money issues, I am done with investing. These days it's all short sellers and day traders who profit. Long term investors are getting screwed big time. Since the company is still afloat, maybe just maybe something good will happen for us. At this point it doesn't pay to sell. I'll just wait it out until the end of the year. GLTU and all who thought this shitty little company would make us some serious money.
Rubber.....yep,I was up nice when this shot up before could of sold but was
greedy (as usual) and blew it......I did the same with another little sub penny
stock I bought about the same time as RVVTF.....bought in at 0.0004 it ran to 4 cents
and I was up 15,000 on a 250 investment..did I sell....NOOOOO and now its back
down to 0.0003.....this stuff isnt for me,I will hold and see what happens,hope it
maybe get back to .15 - .20 and I can break even at some point.
Well said. Penny stocks are always a risk as all of you know. Ups and downs are normal. I'm still hanging on, won't sell, no reason too I don't need the loss until the end of the year. I still have hope I can at least recover my loss by the end of the year.
Noble words in the face of a shitty result It's only. Within 7 months this stock put me in a position to pay off my mortgage and all other debt too. Greed prevented me from doing so. And here we are, with no one to blame but ourselves.
Lessons learned.
Sooooo. No MF monogrammed sweatpants now?
HAHAHAHAHAHAHA!!!!!
I have no one to blame but myself,really thought they had something and as I said
im ride or die.....well im dead.
Don’t worry ric said he was buying all shares under a nickel
Lost a shit ton of money on this crap. I shoulda, coulda woulda sold a long time ago. I think I am done with the stock market for good. It's never a good time to lose money especially now!! So upset and angry.
just sold. not even joking. left a few "just-in-case". i afforded myself more than i could lose to risk. not having fun
So thats it......probalby with the dump thats coming will just stay and see if I can at least break even in a few years
unless they go bankrupt.....thats enough of stocks for me,not my thing.
......"the Study was not designed to take into account all of the symptom assessments and supporting data outlined in the FDA guidelines to warrant a primary symptom-based endpoint for COVID-19 studies".
As a layman. I read that as "even though guilines were in place, we ignored them and did our own thing."
Am I wrong?
Well, can't sell, too much invested in this stock. I'll have to wait it out and if this continues I'll sell later in the year and take the loss and mend my wounds.
They are clueless. They don’t know what is in the stockholders best interest
I expect lawsuits
Seriously what is the idea now we all gonna cut our loss? File a lawsuit? Wait it out for MF to save the day last minute?
So unfortunately (or maybe fortunately) our trial did not take into account how many boogers would be left in patients nose after the 2 weeks is up
News out rvv sticking with original end points.
Hey bud did you ever try taking a reasonable and therapeutic amount instead of recklessly eating 30 at a time? No? Well I've got news for you about benadryls
For this latest submission they were definitely communicating re the type c meeting but prior to that there may have been but imo it would have been limited.
As I previously mentioned, either the rvv med team is simply inept at comprehending what the fda requires, or the fda is constantly moving the goal posts re what they require for approval of the ep submission.
I can think of no reasons why rvv would deliberately want to continuously delay the process by providing substandard submissions.
There is no present need for additional trial data, nor do I believe that any data from dr fahy's research at ucsf will have little impact on the ep change request so a desire for delays is simply not there.
I am tending to believe that the fda (among others) is at the root of this obvious farce and that the link below possibly indicates the reason why................
FDA authorizes Pfizer’s Covid omicron booster as fourth shot for kids under 5
That mushroom will make you nuts ,it grows here wild in pastures where I live we used to eat them raw about 30 at a time and it was like dropping 3 hits of LSD ,there is no good use for them ,they have no good effects on the brain at all except make you super paranoid
As much as we value our Psilocybin asset, our priority should be on maximizing profits for our shareholders. With a hefty $10 million investment in Psilocybin, it's time for us to consider all options, including a possible sell-out to a larger pharmaceutical company or selling it back to PharmaTher. Our limited working capital forces us to focus on what's profitable for the company. After all, we cannot afford to support the research and development of both Psilocybin and Bucillamine. It's clear from the costs associated with research on Psilocybin-based formulations, which amounted to $637,790 in just six months is higher than bucillamine. That we need to manage our capital more prudently. As we move forward, MF need to make strategic decisions that will benefit our company and our investors.
only money--thought you might enjoy article--I just saw today but RE confirms the viral "hideout"
https://www.ndtv.com/world-news/viruses-hiding-in-body-for-months-could-explain-lingering-long-covid-3858850
No one knows whether the coronavirus or its remnants remain in everyone who's had Covid, or if it's just a group of patients,
--eventually IMHO the long covid patients will fall into 2 groups. 1 group that has remnants or viral persistence. These will need to remove the persistence before any Rx can really help
and #2--a group that their immune system has turned on itself/gone haywire and either presented new symptoms or reactivated old bloodstream /prev virus/symptoms. These will need Rx tailored to which biomarker is inflammed
Even a relatively small number of infected cells could provoke the immune system to produce inflammation, blood clots and other problems associated with long Covid, according to Amy Proal, co-founder of PolyBio Research Foundation
Indeed. The effort by BP funded hedge funds here is way too obvious. Time for MF to raise ante to BILLIONs for a buy out. And to ask the Federal trade commission to investigate BP's miss use of hedge funds to short small drug stocks like $RVVTF.
Game on
If there was a back and forth between the fda and revive we would know what endpoint we should have chose. So this belief that there was communication is bs. Just stop with that. You are embarrassing yourself.
Dumbfounding. One would think after the first correction the FDA would say no we need XYZ. Very bizarre this vague back and forth. As stated either RVVTF is truly inept. Or the FDA is crooked. Both are believable IMO
Perhaps they don’t have any idea on how long it will take to reply?
Unlike previous News Releases this latest one doesn't provide a "goal date". It would be nice to have something to aim for even if the target date is missed, once again.
Weren’t they in constant communications with the FDA?
Something doesn’t seem to make sense
The back and forth between rvv and the fda for the past 6+ months has been extremely odd.
They were supposedly engaging in mutual consultations re the type c meeting to come to an agreed submission but lo and behold the most recent submission was once again deemed lacking in certain areas so its back to the drawing board as is said.
The question is, whos to '''blame"", per say, for past failings, and this most recent shortcoming......is the process being deliberately slow walked for some unknown reason???
Is it that the rvv med team keeps misunderstanding/ignoring the fda's instructions because of ineptitude, or is it that the fda is being vague and as such keeps using this confusion as cover to continuously "raise the bar" re the ep change???
IMO, the fda could simply state exactly what they expect from the submission, which rvv could then incorporate and then present for review so the process could then move to the data review stage.
Again IMO, it simply makes no sense why such a basic step is being prolonged for this length of time, especially when one looks at how much more complex issues (involving BP) have previously been rubber stamped.
Finally per your question, only time will tell since answering that would require actual insight into interactions between both parties, which none of us have.
@white chocolate 250.................was denied a $1M loan by the bank....but was told go add some zeroes to my assets and come back for review. lololololssssss
"Denied" (Deny) is a Synonym of "Turned Down" so you basically did state that the fda Denied rvv.........FALSE!!!!
SYNONYM: a word or phrase that has the same or nearly the same meaning as another word or phrase.
English 101....................
Would you prefer the words denied instead of turned down? They asked for endpoint change with two different endpoints and both times were told no those won’t work. Open your eyes.
Interesting
Didn’t RVVTF state this in November 2022?
“The FDA has now requested additional information, which would include clinical data, for them to agree on the Study’s revised endpoints. The Company plans to go over with the FDA the overall development plan for Bucillamine in COVID-19 and further review the Pre-Dose selection data that would support the appropriate endpoints.”
Are they going to provide the FDA with what they are looking for now?
i am trusting the science
Gatorade
The shot (aka) does not prevent the virus infection. Only in some cases somewhat mitigates the severity of the Chinese virus buy with numerous debilitating side effects.
and both times got turned down
Seems theres a serious issue with basic comprehension......rvv was never TURNED DOWN.
There were issues with their applications and the FDA made recommendations for changes and rvv complied, so the process continues.
I will reiterate......posting false info is deceptive.
As for the placebo issue, as I stated before I did my DD and found no such info but I chose not screech daily about it since I can neither confirm, nor deny that claim with 100% certainty.
I can however challenge the lie that rvv has been TURNED DOWN with full confidence!!!
:)) I remember that commercial like it was yesterday.
Rubber.....that was great.....almost pee my pants.
p.s How do you even find something like that.
Haha posting inaccurate information? First time was pcr and they told him to try again. Second time was 2 symptoms and they told him try again.
You want to talk about inaccurate information just look at the post claiming there was a death and multiple icu admissions. Yet when questioned these guys can’t produce the evidence. You didn’t comment on that inaccurate info did you?
theswordman...just seeing some here with long covid & a family member that has issues, it would be a great thing if we get approval and "B" works the way we hope. I never really understood all the technical lingo and appreciate it when people who do great DD put it in terms that a average joe can understand.
So this can be explained by viral persistence. There is a disconnect in medical community where a lot/most Drs (even Patterson et al) believe that as there is no replication (PCR negative) there is not a viral issue.
BUT--if you read other papers/Drs--they show where even the PCR negative patient--tests are positive thru stool test. So even though there is no viral replication--there is viral persistence
Easy enough if you visualize the folds/turns just in 20+ ft of intestine alone. Add in some endothelial damage etc and any organ can be damaged. Happens fast--for some. For others it is taking time but will not end well, damage is damage. Slow or fast
A new study published in Nature Communications aims to shed at least some light on common long COVID symptoms. The study analyzed data from 154,068 people in the Veterans Health Administration system who had COVID-19 and compared it to about 5.6 million people with similar characteristics who did not have the virus. The researchers discovered that people who had COVID-19 were 36% more likely to develop long-term gastrointestinal issues they didn’t have before they got the virus. More than 9,600 of those patients who had COVID-19 developed issues with their digestion, intestines, pancreas, or liver.
Lets hope Bucillamine can be a great treatment for some of the issues with long covid.
New York City Rats Carry COVID-19, Study Finds
3
Simmone Shah
Fri, March 10, 2023 at 1:50 PM EST·2 min read
nyc-rat
insert-text-here
A rat is seen in a street of New York City on Oct. 19, 2022. Credit - Lokman Vural Elibol/Anadolu Agency—Getty Images
A new study has found that not even New York City’s rats are immune to COVID-19.
The study, published in mBio, the American Academy of Microbiology’s journal, found that wild rats in the city’s sewer system and elsewhere in the city have been exposed to SARS-CoV-2 and demonstrated that rats are susceptible to infection with Alpha, Delta, and Omicron variants of the virus.
“Our findings highlight the need for further monitoring of SARS-CoV-2 in urban rat populations and for evaluating the potential risk of secondary zoonotic transmission from these rat populations back to humans,” the authors wrote in the study.
The researchers wanted to understand whether the virus in humans had been transmitted to rats, as well as which variants rats were susceptible to. The team set up two trappings near locations surrounding wastewater systems and captured 79 rats from three sites in and around city parks in Brooklyn in the fall of 2021, when Delta was dominant.
Read More: Why Animals Are Less Vulnerable Than Humans to Omicron
Thirteen of the rats (about 16%) tested positive for COVID-19, and the researchers used genomic analyses to determine a possible link to the viruses that were circulating in humans during the early stages of the pandemic. “To the best of our knowledge, this is one of the first studies to show SARS-CoV-2 variants can cause infections in the wild rat populations in a major U.S. urban area,” said Henry Wan, director of the Center for Influenza and Emerging Infectious Diseases at the University of Missouri and the study’s principal investigator, in a news release.
By giving wild rats samples of different variants through the nose, the researchers also found that Alpha, Delta, and Omicron were able to infect the rats.
The U.S. Centers for Disease Control and Prevention says that there is little risk of animals spreading COVID-19 to humans. But Wan said the findings highlight the need for continued monitoring of rats to watch for potential evolution of new strains of the virus that could be a risk to humans.
“Overall, our work in this space shows that animals can play a role in pandemics that impact humans, and it’s important that we continue to increase our understanding so we can protect both human and animal health,” he said.
Followers
|
338
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36616
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |